ReviewA concise review of serum markers for hepatocellular cancer
Section snippets
Review criteria
We performed a MEDLINE search of the PubMed database by combining the keywords ‘hepatocellular cancer’ and ‘serum marker’ for all journals published in the English language from 2001 to 2006. The search was limited to ‘human subjects’. Studies based on measurements of messenger RNAs, DNA or DNA polymorphisms, lipids, or bile acids as markers were excluded. Anecdotal reports, uncontrolled studies, or studies in which the sensitivity or specificity of a given marker was not provided were
α-Fetoprotein
Alpha-fetoprotein (AFP) is an oncofetal glycoprotein of unknown function that is present at increased levels in sera of patients with cirrhosis and HCC. AFP was discovered by Abelev et al. [6]. The first quantitative serum assays for AFP were established by Ruoshlati and Seppala [7], and their performance has been extensively evaluated. The sensitivity and specificity of AFP in HCC screening and surveillance studies varies according to test thresholds, study designs, and patient populations
Squamous cell carcinoma antigen
Squamous cell carcinoma antigen (SCCA) is a serine protease inhibitor (serpin) that is expressed in many normal squamous epithelial cells [73]. Increased SCCA levels have been found in head and neck cancer tissues and other epithelial cancers [74].
Gianelli and colleagues performed ELISA measurements of serum SCCA in patients with HCC (n = 120), cirrhosis (n = 90), and healthy subjects (n = 41) [75] (Xeptagen, Naples, Italy). SCCA levels were significantly increased in HCC patients as compared to
Serum proteomics
Serum proteomics studies were traditionally based on two-dimensional gel electrophoresis, although this method is insufficiently sensitive to detect low-abundance proteins [76]. Steel and co-workers performed 2-dimensional gel electrophoresis on sera from HBV-infected patients with and without HCC. Two protein signals – corresponding to C3 complement and apolipoprotein A1, respectively – were consistently less abundant in HCC patients as compared to HBV-negative controls and HBV-carriers [77].
HCC-specific auto-antibodies
An extensive body of literature has documented the presence of tumor-derived autoantibodies (TAA) in the sera of HCC patients. They include some of the earliest TAAs, such as anti-p53 [95], as well as new members (such as anti-telomerase [96]). TAAs may be markers of the malignant transformation since their occurrence appears to be triggered by the abnormal processing of antigenic cellular proteins during carcinogenesis [97], [98].
A common feature of HCC-TAAs is their low sensitivity—they are
Conclusion and outlook
The HCC serum marker field is primed for a new generation of candidate markers that have the potential to replace its flawed leader AFP (Table 2). Novel approaches involving serum proteomics and autoantibody discovery should result in the identification of new candidates in the near future. The strict application of the EDRN criteria will aid in the assessment of their diagnostic utility, and provide an objective basis for the assessment of their clinical utility.
Conflict of interest
None declared.
Acknowledgement
This study was supported by a VA Merit Review to C.J.F.
References (106)
- et al.
Serum alpha-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of hbsag and anti-hcv status
J Hepatol
(2001) Alphafetoprotein: an obituary
J Hepatol
(2001)- et al.
Lectin-reactive profiles of alpha-fetoprotein characterizing hepatocellular carcinoma and related conditions
Gastroenterology
(1990) - et al.
Afp-l3: a new generation of tumor marker for hepatocellular carcinoma
Clin Chim Acta
(2001) - et al.
Simultaneous determination of percentage of lens culinaris agglutinin-reactive alpha-fetoprotein and alpha-fetoprotein concentration using the libasys clinical auto-analyzer
Clin Chim Acta
(2003) - et al.
Prospective study of screening for hepatocellular carcinoma in caucasian patients with cirrhosis
J Hepatol
(1994) - et al.
Des-gamma carboxyprothrombin can differentiate hepatocellular carcinoma from nonmalignant chronic liver disease in American patients
Hepatology
(2003) - et al.
A study of lysosomal enzyme activities in serum and leukocytes in chronic hepatic disease (author's transl)
Clin Chim Acta
(1980) - et al.
Mammalian alpha-l-fucosidases
Comp Biochem Physiol B
(1991) - et al.
Oci-5/rat glypican-3 binds to fibroblast growth factor-2 but not to insulin-like growth factor-2
J Biol Chem
(1997)
Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma
Gastroenterology
Glypican-3, overexpressed specifically in human hepatocellular carcinoma, is a novel tumor marker
Biochem Biophys Res Commun
Expression of gp73, a resident golgi membrane protein, in viral and nonviral liver disease
Hepatology
Gp73, a resident golgi glycoprotein, is a novel serum marker for hepatocellular carcinoma
J Hepatol
Hepatocyte growth factor, its receptor, and their potential value in cancer therapies
Crit Rev Oncol Hematol
Clinical relevance of circulating angiogenic factors in patients with non-hodgkin's lymphoma or hodgkin's lymphoma
Leuk Res
Plasma hepatocyte growth factor is increased in early-phase sepsis
J Infect Chemother
Detection of serum and intrahepatic kl-6 in anti-hcv positive patients with hepatocellular carcinoma
Hepatol Res
Proteomics for hepatocellular carcinoma marker discovery
Gastroenterology
The human plasma proteome: history, character, and diagnostic prospects
Mol Cell Proteomics
Mass spectrometry as a diagnostic and a cancer biomarker discovery tool: opportunities and potential limitations
Mol Cell Proteomics
Proteome analysis of hepatocellular carcinoma
Biochem Biophys Res Commun
Clinical evaluation of autoantibodies to p53 protein in patients with chronic liver disease and hepatocellular carcinoma
Eur J Cancer
Phases of biomarker development for early detection of cancer
J Natl Cancer Inst
Screening tests for hepatocellular carcinoma in patients with chronic hepatitis c: a systematic review
Hepatology
Test characteristics of alpha-fetoprotein for detecting hepatocellular carcinoma in patients with hepatitis c: a systematic review and critical analysis
Ann Intern Med
Production of embryonal alpha-globulin by transplantable mouse hepatomas
Transplantation
Studies of carcino-fetal proteins. 3. Development of a radioimmunoassay for -fetoprotein. Demonstration of -fetoprotein in serum of healthy human adults
Int J Cancer
Early recognition of hepatocellular carcinoma based on altered profiles of alpha-fetoprotein
N Engl J Med
‘Hepatoma-specific’ alphafetoprotein may permit preclinical diagnosis of malignant change in patients with chronic liver disease
Br J Cancer
Quantification and utility of monosialylated alpha-fetoprotein in the diagnosis of hepatocellular carcinoma with nondiagnostic serum total alpha-fetoprotein
Clin Chem
Processing of prothrombin in the secretory pathway
Biochem J
Des-gamma-carboxy (abnormal) prothrombin and hepatocellular carcinoma: a critical review
Hepatology
Serum des-gamma-carboxyprothrombin level by a modified enzyme immunoassay method in hepatocellular carcinoma: clinical significance in small hepatocellular carcinoma
Hepatogastroenterology
The usefulness of determining des-gamma-carboxy prothrombin by sensitive enzyme immunoassay in the early diagnosis of patients with hepatocellular carcinoma
Cancer
Serum levels of des-gamma-carboxy prothrombin measured using the revised enzyme immunoassay kit with increased sensitivity in relation to clinicopathologic features of solitary hepatocellular carcinoma
Cancer
Des-gamma-carboxy (abnormal) prothrombin as a serum marker of primary hepatocellular carcinoma
N Engl J Med
Serum des-gamma-carboxyprothrombin concentration determined by the avidin–biotin complex method in small hepatocellular carcinomas
Cancer
Early diagnosis of hepatocellular carcinoma using a sensitive assay for serum des-gamma-carboxy prothrombin: a prospective study
Hepatogastroenterology
Usefulness of serum des-gamma-carboxy prothrombin in detection of hepatocellular carcinoma
World J Gastroenterol
Serum alpha-l-fucosidase: a new marker for the diagnosis of primary hepatic carcinoma?
Hepatology
Serum alpha-l-fucosidase. A useful marker in the diagnosis of hepatocellular carcinoma
Cancer
Serum alpha-l-fucosidase activity and early detection of hepatocellular carcinoma: a prospective study of patients with cirrhosis
Cancer
Alpha-l-fucosidase as a serum marker of hepatocellular carcinoma in southern african blacks
Br J Cancer
Cloning and expression of a developmentally regulated transcript mxr7 in hepatocellular carcinoma: biological significance and temporospatial distribution
Cancer Res
Enhanced glypican-3 expression differentiates the majority of hepatocellular carcinomas from benign hepatic disorders
Gut
Mutations in gpc3, a glypican gene, cause the simpson-golabi-behmel overgrowth syndrome
Nat Genet
Identification of soluble nh2-terminal fragment of glypican-3 as a serological marker for early-stage hepatocellular carcinoma
Cancer Res
Identification of glypican-3 as a novel tumor marker for melanoma
Clin Cancer Res
Elevated levels of transforming growth factor beta messenger rna and its polypeptide in human hepatocellular carcinoma
Cancer Res
Cited by (96)
Design and preparation of a near-infrared-emissive nanosensor for the quantification and imaging of alpha-fetoprotein in vitro and in vivo
2023, Sensors and Actuators B: ChemicalCitation Excerpt :Since this time, AFP has been widely used in the clinical study of a variety of diseases [18]. It has been reported that the serum AFP concentration in the healthy human body is less than 20 ng/mL [19], but higher level can be found in the serum of patients suffering from the liver cancer [20]. And in some patients with primary liver cancer AFP levels are often higher than 500 ng/mL.
An endonuclease-linked multiplex immunoassay for tumor markers detection based on microfluidic chip electrophoresis for DNA analysis
2018, Sensors and Actuators, B: ChemicalCitation Excerpt :Multiplex detection of tumor markers (TMs) can remarkably increase the accuracy of early diagnosis of cancers. For example, CEA, AFP and CA199 had a certain value in the diagnosis of lung cancer, especially the combined detection of tumor markers can effectively improve the accuracy of diagnosis of lung cancer to 95% [1–5]. During these years, many sensitive immunoassay, e.g enzyme-linked immuno sorbent assay [6–8], electrochemical immunosensor [9–13], fluorescent immuno-assay [14,15] have been reported to apply in TM detection with high selectivity and efficiency [16–21].
A novel signal-on photoelectrochemical immunosensor for detection of alpha-fetoprotein by in situ releasing electron donor
2017, Biosensors and Bioelectronics